{"id":"W4236986578","doi":"10.1158/1538-7445.sabcs16-ot2-01-01","title":"Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with <i>PIK3CA-</i>mutant tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Calgary","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Medicine; Internal medicine; Estrogen receptor; Cancer; Aromatase inhibitor; Breast cancer; Oncology; Estrogen; Placebo; PI3K/AKT/mTOR pathway; Endocrinology; Cancer research; Aromatase; Biology; Pathology; Apoptosis; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006535408,0.0006841174,0.001269414,0.0003088308,0.000813359,0.000107006,0.0008623262,0.0001087079,0.0003325258],"category_scores_gemma":[0.00029164,0.0004016305,0.0001342837,0.0008426287,0.001222496,0.0006872314,0.0002219849,0.0009690504,0.000002956785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001679541,"about_ca_system_score_gemma":0.002543611,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00512783,"about_ca_topic_score_gemma":0.004737072,"domain_scores_codex":[0.9940724,0.0002987822,0.0009160822,0.001164373,0.002269255,0.001279149],"domain_scores_gemma":[0.994664,0.0004114702,0.0008479825,0.001404719,0.002209869,0.000462009],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4865856,0.01802209,0.3737786,0.001298495,0.002578375,0.0002041259,0.01072079,0.001790157,0.01430364,0.00002277561,0.000247972,0.09044739],"study_design_scores_gemma":[0.1941979,0.01362381,0.7604734,0.004271916,0.0004104157,0.000008915224,0.006109778,0.00005431722,0.01971378,0.00004177807,0.0002299098,0.0008640976],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849516,0.0002643114,0.00005562265,0.0005109006,0.0001859985,0.01109936,0.002861853,0.00003506762,0.00003529264],"genre_scores_gemma":[0.9953821,0.00007575689,0.0004838703,0.00009800621,0.0001518606,0.003424302,0.00009525343,0.0001741988,0.0001146442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3866948,"threshold_uncertainty_score":0.9998435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02965572347447072,"score_gpt":0.3682503041920291,"score_spread":0.3385945807175584,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}